This is one of the most common reasons men delay a biopsy that could save their life. A urological surgeon addresses the cancer seeding myth directly — with evidence — and explains what the procedure actually involves.
In my outpatient clinic, I see it regularly. A man with an elevated PSA, an MRI showing a suspicious lesion, every clinical indicator pointing toward the need for a prostate biopsy — who refuses. When I ask why, the answer is often some version of: "Doctor, I heard that if you put a needle in, the cancer spreads through the needle track."
This belief — needle tract seeding, or cancer spread from biopsy — is one of the most damaging medical myths I encounter. Not because it is remotely true, but because of what it costs the men who believe it: months or years of delay during which a curable cancer advances to one that is not.
Let me address it directly.
Multiple large studies involving thousands of patients have examined whether prostate biopsy causes cancer seeding along the needle track. The answer, consistently, is no. There are no credible, peer-reviewed studies demonstrating clinically meaningful needle tract seeding from transrectal or transperineal prostate biopsy. This is not a matter of ongoing debate in urological literature — it is settled.
The concept of needle tract seeding does exist in oncology — it is a theoretically possible phenomenon in some cancers, and there are isolated case reports for certain tumour types. But prostate cancer is specifically not among them for several important biological reasons:
If needle seeding from prostate biopsy were real and clinically significant, we would see it — in pathology reports, in imaging follow-up, in survival statistics. We do not. The absence of evidence over many decades of widespread practice is itself strong evidence of absence.
The cancer seeding belief likely has several origins. It is biologically intuitive — putting a needle into a cancer and pulling it out does sound like it could drag cells along. It is consistent with a more general fear of interfering with cancer — the belief, common in many cultures including India, that cancer is better left undisturbed.
It is also spread through community networks with extraordinary efficiency. One person shares the belief, it resonates with existing fears, and it travels. By the time it reaches a patient sitting across from me, it often comes with a specific person's name: "my uncle's friend had a biopsy and the cancer spread."
The reality in that story — when one actually traces it — is almost always that the cancer was already advanced at the time of biopsy, and what appeared to be spread after biopsy was spread that was already present and detected subsequently. The biopsy did not cause the spread. It revealed the extent of disease that already existed.
Prostate cancer caught at Stage I or II has a near 100% 10-year survival. Prostate cancer caught at Stage IV — with metastases to bones or lymph nodes — has a fundamentally different prognosis. The biopsy does not change the biology of the cancer. Delay does.
A prostate biopsy takes 15–20 minutes, is performed under local anaesthesia, and involves a thin needle that takes small tissue samples from specific areas of the prostate. It is an outpatient procedure. Most men return to normal activity the following day.
A prostate biopsy involves passing a thin needle into the prostate to take small tissue samples (cores) that are examined under a microscope. The procedure is guided by ultrasound and increasingly uses MRI-fusion technology to target suspicious areas identified on prior MRI scanning.
Local anaesthetic is injected around the prostate before the biopsy — a periprostatic nerve block — which makes the procedure significantly more comfortable. The actual needle passes take a fraction of a second each. Most patients describe the experience as uncomfortable but not severely painful.
The procedure takes 15–20 minutes. You go home the same day. Most men return to work and normal activities within 24–48 hours.
Transrectal ultrasound-guided biopsy taking 10–12 cores systematically from the prostate. Widely available but misses anteriorly located tumours and cannot specifically target MRI lesions.
The MRI image is overlaid onto the real-time ultrasound image, allowing the needle to be directed precisely to the suspicious lesion identified on MRI. More accurate, fewer unnecessary cores, higher detection rate for clinically significant cancer. This is the current standard of care.
Traditionally, prostate biopsies were performed via the transrectal route — through the rectal wall. The transperineal approach — through the skin between the scrotum and anus — is increasingly preferred as it has a significantly lower infection risk (avoiding the bacteria-laden rectal environment). Many centres have now moved to transperineal as the standard approach.
Fever above 38.5°C, inability to pass urine, heavy bright red bleeding, or feeling very unwell — go to the emergency department immediately. Post-biopsy sepsis is rare but serious and requires prompt antibiotic treatment.
The prostate biopsy is not your enemy. It is the instrument of certainty in a situation otherwise dominated by uncertainty. It tells you whether you have cancer and if so, what type — information that is the foundation of every subsequent decision.
The fear of the biopsy — particularly the cancer seeding myth — has cost lives. Men who delayed by months or years waiting for a reason not to have the biopsy, while a curable cancer became incurable.
If your urologist has recommended a biopsy, the reason is that your clinical picture warrants one. The biopsy will not make things worse. Not having it might.
This article is written to address common patient concerns about prostate biopsy and does not constitute medical advice. The decision to perform a biopsy is made by a qualified urologist based on individual clinical findings. If you have concerns about a recommended biopsy, discuss them directly with your urologist rather than postponing the procedure without medical guidance.